JPH05124958A - Composition having lipidperoxide-lowering activity - Google Patents

Abstract

PURPOSE:To provide a composition containing carotenoid and lecithin as main ingredients and having a lipidperoxide-lowering action. CONSTITUTION:The objective composition contains 0.1-10 pts. of carotenoid and 99.9-90 pts. of lecithin preferably in a compounding ratio of 1:(99-95). The cartenoid is a strongly lipophilic substance and includes beta-carotene and astaxanthine, and the lecithin as a phospholipid includes soybean lecithin and york lecithin. The composition containing the homogeneous mixture of the carotenoid with the lecithin exhibits an action to reduce the increase in the amount of lipidperoxide in a living body by its oral administration, etc., the increase being recognized in the patients of hypertension, diabetes, cerebral hemorrhage, cancer, etc.

Description

Detailed Description of the Invention

[0001]

TECHNICAL FIELD The present invention relates to a composition having a lipid peroxide lowering action, and more particularly to a composition having a lipid peroxide lowering action containing carotenoid and lecithin as main components.

[0002]

2. Description of the Related Art Carotenoids widely distributed and present in the animal and plant kingdom have hitherto been regarded only to the extent that some of them have provitamin A activity. Widely known are yellow to red pigments. These are aliphatic or cycloaliphatic polyenes containing a large number of double bonds. Since carotenoids are sensitive to air, light, acid, heat, metal ions, etc. and are susceptible to these actions and change easily, they are coated with gelatin etc. to stabilize them.

Carotenoid is a substance having a strong lipophilicity, and its absorption into the living body cannot be said to be good. In addition, in order to achieve stabilization, various coating agents may be used or compounding agents may be added, but their absorption efficiency is extremely low.

[0004] Lipid peroxide is present in the living body, and its amount increases with age, and it is often used as an index of tissue deterioration, which is well-matched with hypertension, diabetes, stroke, and the age at which cancer rapidly increases, which is said to be an adult disease. I am doing it.

[0005] Clinically, it is said that a person with severe blood pressure, diabetes, stroke, arteriosclerosis, etc. has a larger amount of lipid peroxide in the blood than a person without it. It is speculated that lipid peroxides are closely related to aging and adult diseases.

[0006]

DISCLOSURE OF THE INVENTION The present inventors have focused on the antioxidative ability of carotenoids and, when used in combination with lecithin, have significantly improved the in vivo transport and in vivo reactivity,
As a result of studying the administration of this and changes in the amount of lipid peroxide in vivo, it was found that administration of carotenoid and lecithin significantly reduced the amount of lipid peroxide in blood. The present invention has been completed based on these findings. Therefore, the present invention aims to reduce lipid peroxide by administration of carotenoid and lecithin, and provides a formulation suitable for administration.

[0007]

According to the present invention, the amount of lipid peroxide in the blood can be maintained at a low level by administering a carotenoid-treated lecithin-treated mixture and ingesting a mixture containing the treated mixture. The use of said carotenoid-lecithin treatment formulation is provided.

Carotenoids that can be used here include β-carotene, canthaxanthin, astaxanthin, rutin, α-carotene, γ-carotene, lycopene, cryptoxanthin, zeaxanthin,
Examples thereof include rhodoxanthin, capsanthin, β-apo-8′-carotate ethyl ester, citranaxanthin, echinenone, phenicoxanthin, tunaxanthine, doradixanthine, and derivatives thereof.

All of these are polyterpenes having isoprene as a constitutional unit, which are widely distributed and exist in the natural world and are produced by extraction or by chemical synthesis and bacterial cells.

On the other hand, lecithin is a kind of lipid called phospholipid and is represented by the following structural formula 1.

[0011]

[Chemical 1] In the formula, —COR ₁ and —COR ₂ represent fatty acid residues, and B represents residues of choline, ethanolamine, myoinositol, and serine.

Specifically, soybean lecithin, egg yolk lecithin, modified lecithin thereof and the like are known, and any of them can be used for the purpose of the present invention.

Carotenoids are dispersed and dissolved in lecithin,
It is encapsulated, and its mixing ratio is 0.1-0.1
Lecithin is 99.9 to 90 parts with respect to 10 parts. Desirably, it is 1:99 to 5:95. If desired, the composition of the present invention may further contain other additives, solvents and drugs. It has also been found that a mixture of lecithin with animal and vegetable oils and fatty acids can be preferably used instead of lecithin.

The animal and vegetable oils used include germinal oil, soybean oil, olive oil, rapeseed oil, perilla oil, corn oil, other vegetable oils, cod liver oil, cod egg oil, salmon oil, whale liver oil and other animal oils and fats.

The production of a carotenoid and lecithin or a mixture of lecithin and oil is carried out as follows. That is, crude lecithin alone or high purity lecithin and 1-2
The cracked vegetable oil is put in, for example, a kneader-type blender or a Surikogi-type kneader, and a predetermined amount of carotenoid is added to the kneaded portion and kneaded sufficiently. This kneading produces a formulation according to the invention of carotenoids and lecithin.

The thus-obtained composition according to the present invention was made into a form in which it can be ingested in an appropriate amount, and when it was ingested at a normal meal, it was found that it functions to lower the amount of lipid peroxide in blood. Was issued. Hereinafter, the present invention will be described more specifically by describing examples. However, this does not limit the present invention in any way.

[0017]

[Example 1] 96 g of lecithin (soybean lecithin) was placed in a Sericho type kneader, and then 2.0 g of astaxanthin
Then, 2.0 g of β-carotene was added and kneading was continued for 60 minutes. The obtained blended and kneaded product was used as a gelatin capsule containing 350 mg each.

The above-obtained capsules were used for A ward: 21 to 30 years old, 8 healthy persons, B ward: 41 to 50 years, 9 healthy persons, C ward: 61 years or older, 6 healthy persons, D zone: 41 to 50 years, healthy person. The group members of 11 persons (control group) were ingested 2 capsules after breakfast and 2 capsules after dinner every day for 8 weeks continuously per person. The group D (control group) was not ingested with the composition according to the present invention, and the diet was the same as the others.

In order to measure the amount of lipid peroxides, blood was collected from each group member by determining the start date and every week every week before dinner at 5 to 6 pm, and used as samples. The amount of lipid peroxide was quantified by the TBA fluorescence method (Yagi method). That is,
Malondialdehyde, which is formed when lipid peroxide is decomposed, produces TBA (thiobarbiluri aci) under acidic conditions.
The red-colored substance produced by the reaction with d) is quantified by the fluorescence method. Besides malondialdehyde,
A substance having a red color was formed by reacting with TBA, and it was also quantified for convenience that it depends on malondialdehyde.

The fluorescence intensity (f) of the sample is measured at an excitation wavelength of 515n.
m, the fluorescence wavelength was 553 nm, and the fluorescence intensity (F) of the standard sample was also measured in the same manner as the sample. The amount of lipid peroxide in blood was calculated according to the following formula. Peroxide concentration (nmol
/ Ml blood) = f / F × 21 nmol / ml blood.

The results are shown in Table 1.

[Table 1] If this is graphed, it becomes as shown in FIG.

[Figure 1]

[0022]

[Brief description of drawings]

The horizontal axis is the week of intake, and the vertical axis is the average blood lipid peroxide amount nm
ol MDA / ml, A, B, C, D are target categories (A
Means a group of 21 to 30 years old, B means a group of 41 to 50 years old, C means a group of 61 years old or older, and D means a group of 41 to 50 years old (control).

─────────────────────────────────────────────────── ───

[Procedure amendment]

[Submission date] November 6, 1992

[Procedure Amendment 1]

[Document name to be amended] Statement

[Correction target item name] 0021

[Correction method] Change

[Correction content]

The results are shown in Table 1.

[Table 1] The graph is shown in FIG.

[Procedure Amendment 2]

[Document name to be amended] Statement

[Name of item to be corrected] 0022

[Correction method] Change

[Correction content]

[0022]

[Brief description of drawings]

[FIG. 1] The horizontal axis represents the week of intake, the vertical axis represents the mean blood lipid peroxide amount nmolMDA / ml, and A, B, C, and D are target categories (A is a group of 21 to 30 years old, B is 41). ~ 50 year old croup, C 61 year old or older, D 41 ~ 5
It means a group of 0 years old (target area).

─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. ⁵ Identification code Office reference number FI technical display area A61K 47/24 J 7329-4C

Claims (2)

[Claims] 1. A composition having an action of lowering lipid peroxide, which comprises an essential mixture of a homogeneous mixture of carotenoid and lecithin. 2. A composition having a lipid peroxide-lowering effect, which comprises 99.9 to 90 parts of lecithin mixed with 0.1 to 10 parts of carotenoid. Composition.